Shield Therapeutics is a commercial stage biotechnology company that delivers innovative specialty pharmaceuticals to address significant unmet needs in the treatment of iron deficiency and hyperphosphatemia.
Our lead product ACCRUFeR® (ferric maltol) is a novel, stable, non-salt based oral therapy and is approved in the United States, European Union, UK and Switzerland for the treatment of iron deficiency with or without anemia in adults.